608 related articles for article (PubMed ID: 21532596)
1. Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones.
Lu M; Sarruf DA; Talukdar S; Sharma S; Li P; Bandyopadhyay G; Nalbandian S; Fan W; Gayen JR; Mahata SK; Webster NJ; Schwartz MW; Olefsky JM
Nat Med; 2011 May; 17(5):618-22. PubMed ID: 21532596
[TBL] [Abstract][Full Text] [Related]
2. Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice.
Duan SZ; Usher MG; Foley EL; Milstone DS; Brosius FC; Mortensen RM
Diabetologia; 2010 Jul; 53(7):1493-505. PubMed ID: 20401461
[TBL] [Abstract][Full Text] [Related]
3. A role for central nervous system PPAR-γ in the regulation of energy balance.
Ryan KK; Li B; Grayson BE; Matter EK; Woods SC; Seeley RJ
Nat Med; 2011 May; 17(5):623-6. PubMed ID: 21532595
[TBL] [Abstract][Full Text] [Related]
4. Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism.
Dallaire P; Bellmann K; Laplante M; Gélinas S; Centeno-Baez C; Penfornis P; Peyot ML; Latour MG; Lamontagne J; Trujillo ME; Scherer PE; Prentki M; Deshaies Y; Marette A
Diabetes; 2008 Aug; 57(8):1999-2011. PubMed ID: 18458147
[TBL] [Abstract][Full Text] [Related]
5. Endothelial Cell-Targeted Deletion of PPAR
Akiyama TE; Skelhorne-Gross GE; Lightbody ED; Rubino RE; Shi JY; McNamara LA; Sharma N; Zycband EI; Gonzalez FJ; Liu H; Woods JW; Chang CH; Berger JP; Nicol CJB
J Pharmacol Exp Ther; 2019 Mar; 368(3):514-523. PubMed ID: 30606762
[TBL] [Abstract][Full Text] [Related]
6. PPAR-γ action: it's all in your head.
Myers MG; Burant CF
Nat Med; 2011 May; 17(5):544-5. PubMed ID: 21546969
[No Abstract] [Full Text] [Related]
7. Impact of increased PPARgamma activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment.
Takasawa K; Kubota N; Terauchi Y; Kadowaki T
Endocr J; 2008 Aug; 55(4):767-76. PubMed ID: 18506083
[TBL] [Abstract][Full Text] [Related]
8. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones.
Hevener AL; Olefsky JM; Reichart D; Nguyen MT; Bandyopadyhay G; Leung HY; Watt MJ; Benner C; Febbraio MA; Nguyen AK; Folian B; Subramaniam S; Gonzalez FJ; Glass CK; Ricote M
J Clin Invest; 2007 Jun; 117(6):1658-69. PubMed ID: 17525798
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reverses the adverse effects of diet-induced obesity on oocyte quality.
Minge CE; Bennett BD; Norman RJ; Robker RL
Endocrinology; 2008 May; 149(5):2646-56. PubMed ID: 18276752
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
Derosa G; Maffioli P
Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
[TBL] [Abstract][Full Text] [Related]
11. Muscle-specific Pparg deletion causes insulin resistance.
Hevener AL; He W; Barak Y; Le J; Bandyopadhyay G; Olson P; Wilkes J; Evans RM; Olefsky J
Nat Med; 2003 Dec; 9(12):1491-7. PubMed ID: 14625542
[TBL] [Abstract][Full Text] [Related]
12. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.
Gregoire FM; Zhang F; Clarke HJ; Gustafson TA; Sears DD; Favelyukis S; Lenhard J; Rentzeperis D; Clemens LE; Mu Y; Lavan BE
Mol Endocrinol; 2009 Jul; 23(7):975-88. PubMed ID: 19389808
[TBL] [Abstract][Full Text] [Related]
13. PPARγ agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets.
Pipatpiboon N; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
Endocrinology; 2012 Jan; 153(1):329-38. PubMed ID: 22109891
[TBL] [Abstract][Full Text] [Related]
14. The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism.
Vigueira PA; McCommis KS; Hodges WT; Schweitzer GG; Cole SL; Oonthonpan L; Taylor EB; McDonald WG; Kletzien RF; Colca JR; Finck BN
Exp Physiol; 2017 Aug; 102(8):985-999. PubMed ID: 28597936
[TBL] [Abstract][Full Text] [Related]
15. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.
Mensink M; Hesselink MK; Russell AP; Schaart G; Sels JP; Schrauwen P
Int J Obes (Lond); 2007 Aug; 31(8):1302-10. PubMed ID: 17310221
[TBL] [Abstract][Full Text] [Related]
16. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
17. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
18. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice.
Duan SZ; Ivashchenko CY; Russell MW; Milstone DS; Mortensen RM
Circ Res; 2005 Aug; 97(4):372-9. PubMed ID: 16051889
[TBL] [Abstract][Full Text] [Related]
19. CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo.
Ming Y; Hu X; Song Y; Liu Z; Li J; Gao R; Zhang Y; Mei H; Guo T; Xiao L; Wang B; Wu C; Xiao X
PLoS One; 2014; 9(7):e102102. PubMed ID: 25004107
[TBL] [Abstract][Full Text] [Related]
20. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
Simó R; Rodriguez A; Caveda E
Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
